|Slideshows|July 28, 2017

New Insights on Substance Use Disorders

A clinical collection on addiction treatment, ADHD and SUDs, important drug indications, vaping, cannabis use, benzodiazepines, the perils of self-medicating and other topics relevant to practicing psychiatrists.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High

ByPsychiatric Times Editors

August 31st 2026

First Patient Dosed in Phase 3 SUMMIT Trial of AXS-05 for Smoking Cessation

ByLeah Kuntz

August 31st 2026

Morning Rounds: August 24-31

ByJessica Walters

August 31st 2026

Mindfully Prescribing Benzodiazepines in Psychiatry

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 29th 2026

Prescribing Benzodiazepines in Psychiatry, With Carl Salzman, MD

ByJoseph F. Goldberg, MD,Carl Salzman, MD

August 25th 2026

Latest CME

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Gus Alva, MD, DFAPA; Erin Crown, MHS, PA-C

New Insights on Substance Use Disorders

Related Content

International Overdose Awareness Day Marks 25th Year as US Overdose Deaths Decline Yet Remain High

First Patient Dosed in Phase 3 SUMMIT Trial of AXS-05 for Smoking Cessation

Morning Rounds: August 24-31

Mindfully Prescribing Benzodiazepines in Psychiatry

Prescribing Benzodiazepines in Psychiatry, With Carl Salzman, MD

Latest CME

Jersey City Psychiatry

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Cases and Conversations™: Optimizing Administration of Treatment for Patients with Schizophrenia

Trending on Psychiatric Times

When Treatment-Resistant Depression Means Mismatched: Rethinking Difficult-to-Treat Depression

Repurposing Dopamine Agonist Pramipexole for Disabling Anhedonia

Brain Trust: Anita H. Clayton, MD, on Diagnosing and Treating Sexual Dysfunction

The Year So Far in GLP-1s: What Psychiatric Clinicians Need to Know

GLP-1 Receptor Agonists Linked to Lower Mortality, Cardiovascular Events in Serious Mental Illness